Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Syndecan binding protein (SDCBP) is overexpressed in estrogen receptor negative breast cancers, and is a potential promoter for tumor proliferation.

Qian XL, Li YQ, Yu B, Gu F, Liu FF, Li WD, Zhang XM, Fu L.

PLoS One. 2013;8(3):e60046. doi: 10.1371/journal.pone.0060046. Epub 2013 Mar 22.

2.

Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).

Qian XL, Zhang J, Li PZ, Lang RG, Li WD, Sun H, Liu FF, Guo XJ, Gu F, Fu L.

PLoS One. 2017 Jan 31;12(1):e0171169. doi: 10.1371/journal.pone.0171169. eCollection 2017.

4.

Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.

Barone I, Brusco L, Gu G, Selever J, Beyer A, Covington KR, Tsimelzon A, Wang T, Hilsenbeck SG, Chamness GC, Andò S, Fuqua SA.

J Natl Cancer Inst. 2011 Apr 6;103(7):538-52. doi: 10.1093/jnci/djr058. Epub 2011 Mar 29.

6.

miR-216b suppresses breast cancer growth and metastasis by targeting SDCBP.

Jana S, Sengupta S, Biswas S, Chatterjee A, Roy H, Bhattacharyya A.

Biochem Biophys Res Commun. 2017 Jan 1;482(1):126-133. doi: 10.1016/j.bbrc.2016.10.003. Epub 2016 Oct 5.

PMID:
27720715
7.

CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.

Al-Dhaheri M, Wu J, Skliris GP, Li J, Higashimato K, Wang Y, White KP, Lambert P, Zhu Y, Murphy L, Xu W.

Cancer Res. 2011 Mar 15;71(6):2118-28. doi: 10.1158/0008-5472.CAN-10-2426. Epub 2011 Jan 31.

8.

Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.

Zou Y, Tsai WB, Cheng CJ, Hsu C, Chung YM, Li PC, Lin SH, Hu MC.

Breast Cancer Res. 2008;10(1):R21. doi: 10.1186/bcr1872. Epub 2008 Feb 29.

9.

Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.

Vanderlaag KE, Hudak S, Bald L, Fayadat-Dilman L, Sathe M, Grein J, Janatpour MJ.

Breast Cancer Res. 2010;12(3):R32. doi: 10.1186/bcr2586. Epub 2010 Jun 4.

10.
11.

Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.

Syed Khaja AS, Dizeyi N, Kopparapu PK, Anagnostaki L, Härkönen P, Persson JL.

PLoS One. 2013 Aug 8;8(8):e72210. doi: 10.1371/journal.pone.0072210. eCollection 2013.

12.

ER-α36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells.

Deng H, Zhang XT, Wang ML, Zheng HY, Liu LJ, Wang ZY.

PLoS One. 2014 Feb 18;9(2):e88034. doi: 10.1371/journal.pone.0088034. eCollection 2014.

13.

Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.

Nukatsuka M, Saito H, Nakagawa F, Abe M, Uchida J, Shibata J, Matsuo K, Noguchi S, Kiniwa M.

Breast Cancer Res Treat. 2011 Jul;128(2):381-90. doi: 10.1007/s10549-010-1141-3. Epub 2010 Aug 31.

PMID:
20809360
14.

The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.

Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC.

Cancer Res. 2010 Feb 1;70(3):1184-94. doi: 10.1158/0008-5472.CAN-09-3068. Epub 2010 Jan 19.

15.

Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression.

Gangemi R, Mirisola V, Barisione G, Fabbi M, Brizzolara A, Lanza F, Mosci C, Salvi S, Gualco M, Truini M, Angelini G, Boccardo S, Cilli M, Airoldi I, Queirolo P, Jager MJ, Daga A, Pfeffer U, Ferrini S.

PLoS One. 2012;7(1):e29989. doi: 10.1371/journal.pone.0029989. Epub 2012 Jan 13.

16.

Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells.

Chen X, Danes C, Lowe M, Herliczek TW, Keyomarsi K.

J Natl Cancer Inst. 2000 Sep 6;92(17):1403-13.

PMID:
10974076
17.

Unliganded estrogen receptor alpha inhibits breast cancer cell growth through interaction with a cyclin-dependent kinase inhibitor (p21(WAF1)).

Maynadier M, Ramirez JM, Cathiard AM, Platet N, Gras D, Gleizes M, Sheikh MS, Nirde P, Garcia M.

FASEB J. 2008 Mar;22(3):671-81. Epub 2007 Oct 2.

PMID:
17911387
18.

Annexin-1 regulates growth arrest induced by high levels of estrogen in MCF-7 breast cancer cells.

Ang EZ, Nguyen HT, Sim HL, Putti TC, Lim LH.

Mol Cancer Res. 2009 Feb;7(2):266-74. doi: 10.1158/1541-7786.MCR-08-0147. Epub 2009 Feb 10.

19.

Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts.

Chung H, Jung YM, Shin DH, Lee JY, Oh MY, Kim HJ, Jang KS, Jeon SJ, Son KH, Kong G.

Int J Cancer. 2008 Feb 15;122(4):816-22.

20.

Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells.

Jiang C, Guo J, Wang Z, Xiao B, Lee HJ, Lee EO, Kim SH, Lu J.

Breast Cancer Res. 2007;9(6):R77.

Supplemental Content

Support Center